Even for a stem cell research wonk like me the broader regenerative arena never ceases to surprise me with the latest thing being stem cell shampoo. Stem cell shampoo A news item that seems promotional discussed the stem cell shampoo as yielding positive results. So after you are done with your vampire facelift, stem cell […]
Weekly reads: stem cell shampoo, Neobiosis FDA warning, trogocytosis Read More »
When I first saw the new FDA warning on stem cells for pets and the logo for the company that received it, I was surprised in a few ways. I don’t recall ever seeing such a letter and the logo is something else. We’ll get into all of that in a moment, but first, since
Recommended reads: FDA warning on stem cells for pets, chromatin, aging & HSCs Read More »
One of the most contentious areas in the regenerative medicine arena is whether a fat tissue product called stromal vascular fraction or SVF is a drug. The FDA says SVF, even in autologous form, is a drug. It is seeking an injunction against a California-based network of SVF clinics but lost the initial case. That
Recommend reads: FDA SVF warning, big Aspen grant, CSI finale invokes stem cells Read More »
So many things go wrong during the lead up to clinically-evident Alzheimer’s disease. This complex disease pathway has, in turn, led to a vast array of approaches to try to treat or prevent Alzheimer’s. Most of these efforts one way or another have something to do with the amyloid plaques and tangles that accumulate in the
Placental biologics firm MiMedx and exosome company Kimera Labs both recently received FDA warning letters. The letter to MiMedx was related to its placental biologics products and procedures. The new warning to Kimera Labs was about its exosome products and an amniotic product. Let’s compare these letters starting with the one to MiMedX. MiMedx warning letter
Weekly reads: MiMedX & Kimera Labs FDA warnings, NYT on Bryan Johnson, MUSE cell trial Read More »
The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I’ve written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It’s become a puzzling situation. More broadly, the FDA has done relatively little in the past
3rd Invitrx warning highlights FDA oversight weakness Read More »
I’ve tried to find some time to do some stem cell and other regenerative medicine reading too, but it’s been a busy week of teaching for me as a professor in our new academic year for the UC Davis School of Medicine. I help to teach the Histology part of the first-year curriculum. It’s an
Regenerative medicine reads: retraction, FDA warning, CAR-T, ARM CEO Read More »
The last six months I’ve been spending even more time than usual writing NIH grants (and a few others). The last two weeks have been especially busy on this front as I am getting an R01 renewal out the door. My paper reading lately has been mostly related to the grant writing I’m doing. Still,
Weekly reads: NIH grants, side effect of darker hair, FDA warning, CRISPR Read More »
If you celebrate the Thanksgiving holiday I hope you had a nice one and, right before it started a new article popped on the scene about the CRISPR babies. Before we discuss those three gene-edited people, who are now growing up into little kids, we hit a milestone on our YouTube Stem Cell Channel with
Regenerative reads: 3 CRISPR babies, FDA warning, diabetes, pubs Read More »
What can a gecko possibly teach us about skin cancer? Read on. It’s fun when a week’s worth of science reading covers so much territory including COVID-19, geckos that get cancer, a research misconduct sleuth, an FDA letter, and more. Baltimore weighs in on COVID lab origin idea Caltech has a very interesting interview with
Recommended reads: Bik, FDA letter, gecko cancer model, David Baltimore on COVID origin Read More »